To the Editor We appreciate Love and Fathallah-Shaykh1 bringing the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) to the attention of the JAMA Neurology readership, and we would like to address the questions raised around NeuroNEXT plans for intellectual property, data sharing, industry involvement, indemnification, and funds for study oversight. In NeuroNEXT, applicants who use the U01 and U44 mechanisms will maintain intellectual property protections afforded under the Bayh-Dole Act (35 USC 201 and 37 CFR 401) so that ownership of intellectual property remains with the inventing site’s institution.
McNeil E, Gunas H, Koroshetz W. The Future of Neuroscience Clinical Trials. JAMA Neurol. 2014;71(5):652. doi:https://doi.org/10.1001/jamaneurol.2014.165
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: